Synthaverse S.A.

WSE:SVE Voorraadrapport

Marktkapitalisatie: zł307.1m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Synthaverse Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mieczyslaw Starkowicz

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO2.2yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur3.2yrs

Recente managementupdates

Recent updates

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Apr 20
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

Apr 18
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

CEO

Mieczyslaw Starkowicz

2.2yrs

Tenure

Mr. Mieczyslaw Starkowicz serves as President of the Management Board and Chief Executive Officer at Synthaverse S.A. (formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.) since August 202...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Waldemar Sierocki
Secretary of Supervisory Board & Member of Supervisory Boardno datazł24.00k6.48%
PLN 19.9m
Konrad Miterski
Member of the Supervisory Boardno datazł42.00k0.072%
PLN 221.3k
Wiktor Napióra
Vice Chairman of the Supervisory Boardno datazł40.00k7.2%
PLN 22.1m
Dariusz Kucowicz
Member of Supervisory Board16.8yrszł39.00k0.31%
PLN 937.6k
Maciej Korniluk
Member of Supervisory Board1.8yrsgeen gegevensgeen gegevens
Jaroslaw Blaszczak
Chairman of the Supervisory Boardno datazł113.00k2%
PLN 6.2m
Dirk Pamperin
Member of the Supervisory Board4.7yrszł37.00kgeen gegevens
Maciej Siedlar
Member of Supervisory Board1.8yrsgeen gegevens0.14%
PLN 437.8k

3.2yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van SVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).